These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 10488896)
1. DOTS plus strategy in resource-poor countries. Davies PD Int J Tuberc Lung Dis; 1999 Sep; 3(9):843-4. PubMed ID: 10488896 [No Abstract] [Full Text] [Related]
2. Cost-effective control of drug-resistant TB: listening to other voices. Portero JL; Rubio M PLoS Med; 2006 Dec; 3(12):e542. PubMed ID: 17194207 [No Abstract] [Full Text] [Related]
3. DOTS plus strategy in resource-poor countries. Ollé-Goig JE Int J Tuberc Lung Dis; 1999 Sep; 3(9):843; author reply 844. PubMed ID: 10488895 [No Abstract] [Full Text] [Related]
4. Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis, in Ecuador. Rouzier VA; Oxlade O; Verduga R; Gresely L; Menzies D Int J Tuberc Lung Dis; 2010 Oct; 14(10):1316-22. PubMed ID: 20843424 [TBL] [Abstract][Full Text] [Related]
5. [Progress of medicine threatened by drug resistance]. Sante; 2000; 10(5):363-4. PubMed ID: 11221700 [No Abstract] [Full Text] [Related]
6. TB drug prices slashed for poor countries. Hagmann M Bull World Health Organ; 2001; 79(9):904-5. PubMed ID: 11584747 [No Abstract] [Full Text] [Related]
7. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Pablos-Mendez A; Gowda DK; Frieden TR Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008 [TBL] [Abstract][Full Text] [Related]
8. Directly observed treatment for multidrug-resistant tuberculosis: an economic evaluation in the United States of America and South Africa. Wilton P; Smith RD; Coast J; Millar M; Karcher A Int J Tuberc Lung Dis; 2001 Dec; 5(12):1137-42. PubMed ID: 11769772 [TBL] [Abstract][Full Text] [Related]
9. Epidemiological and cost analysis of multidrug-resistant tuberculosis in Oman. Mohammadi A; Nassor ZS; Behlim T; Mohammadi E; Govindarajan R; Al Maniri A; Smego RA East Mediterr Health J; 2008; 14(6):1240-5. PubMed ID: 19161099 [TBL] [Abstract][Full Text] [Related]
11. Do we have evidence for policy changes in the treatment of children with latent tuberculosis infection? Lobato MN; Jereb JA; Castro KG Pediatrics; 2009 Mar; 123(3):902-3. PubMed ID: 19255018 [No Abstract] [Full Text] [Related]
12. Public health. Responding to market failures in tuberculosis control. Gupta R; Kim JY; Espinal MA; Caudron JM; Pecoul B; Farmer PE; Raviglione MC Science; 2001 Aug; 293(5532):1049-51. PubMed ID: 11463877 [No Abstract] [Full Text] [Related]
13. Response to drug resistant tuberculosis is insufficient and too slow. Cui W BMJ; 2011 Mar; 342():d1969. PubMed ID: 21444638 [No Abstract] [Full Text] [Related]
14. Is DOTS-plus a feasible and cost-effective strategy? Garner P; Alejandria M; Lansang MA PLoS Med; 2006 Sep; 3(9):e350. PubMed ID: 16968122 [TBL] [Abstract][Full Text] [Related]
15. [The cost of treatment in new case and multidrug resistant case in pulmonary tuberculosis]. Kizkin O; Hacievliyagil SS; Türker G; Günen H Tuberk Toraks; 2003; 51(4):410-5. PubMed ID: 15143390 [TBL] [Abstract][Full Text] [Related]
16. Why tuberculosis persists as a global problem. Benatar S Int J Tuberc Lung Dis; 2005 Mar; 9(3):235. PubMed ID: 15786883 [No Abstract] [Full Text] [Related]
19. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Loddenkemper R; Sotgiu G; Mitnick CD Eur Respir J; 2012 Jul; 40(1):9-11. PubMed ID: 22753833 [No Abstract] [Full Text] [Related]
20. Latent tuberculosis infection in children: a call for revised treatment guidelines. Finnell SM; Christenson JC; Downs SM Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]